Natco Pharma - Muted Revenue Growth; Agro-Chem To Aid Earnings: Geojit
In the crop health science division CTPR associated products which were launched are expected to drive earnings in the near-term.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Geojit Research Report
Natch Pharma Ltd. is an India-based vertically integrated and research and development focused enterprise, engaged in developing, manufacturing and marketing finished dosage formulations and active pharmaceutical ingredients and intermediates.
Natco witnessed 67% revenue growth in H1 FY23, owing to robust Revlimid sales.
Ebitda margins expanded 1436 basis points to 37% in H1 FY23 from 23% in H1 FY22 led by strong contribution from export formulations.
Export formulation business registered a 204% growth in H1 FY23 with revenues at Rs 1020 crore.
Brazilian and Canadian subs, backed by strong new launches, have reported robust growth with 40-50% share in profitability.
In the crop health science division, the Chlorantraniliprole associated products which were launched are expected to drive earnings in the near-term.
We remain optimistic on Natco’s future profitability backed by the traction in CTPR and Revlimid sales and recovery in domestic formulation.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.